Company Announcement / Press release Archives - Page 3 of 16

New number of shares and votes in Xspray Pharma

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the number of shares and votes in Xspray Pharma AB has changed as a result of shares being registered due to the rights issue which was carried out in June 2023. Through the rights issue, carried out in June 2023, the number of outstanding shares and […]

Xspray Pharma receives request for additional information concerning Dasynoc from FDA

Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) announces an update on recent developments regarding the company’s first product, Dasynoc, currently under review by the United States Food & Drug Administration (“FDA”). The company has received a Complete Response Letter (“CRL”) whereby the FDA request additional information particularly regarding additional information to doctors and users related […]

Xspray raises approximately SEK 251 million through a rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR […]

Xspray has published prospectus relating to its previously announced rights issue

Xspray Pharma AB (publ) (“Xspray” or the “Company”), (NASDAQ Stockholm: XSPRAY) on 2 May 2023 announced a rights issue of units of approximately SEK 300 million (the “Rights Issue”), with two warrant series approximately amounting together up to an additional SEK 300 million upon full exercise. The Board of Directors of the Company resolved on […]

The Board of Directors of Xspray has resolved on a previously announced rights issue of units of approximately SEK 300 million ahead of Dasynoc product launch

Xspray Pharma AB (publ) (“Xspray” or the “Company”), (NASDAQ Stockholm: XSPRAY) announced on 2 May 2023 its intention to carry out a rights issue of units of approximately SEK 300 million (the “Rights Issue”), with two warrant series that together amount to an additional approximately SEK 300 million upon full exercise. The Board of Directors […]

Bulletin from the extraordinary general meeting of Xspray Pharma AB (publ)

The following resolutions were passed at the extraordinary general meeting (the “EGM”) of Xspray Pharma AB (publ) (“Xspray”) on 25 May 2023. Authorisation to issue new shares with deviation from the shareholders’ preferential rightsThe EGM resolved, in accordance with the board of directors’ proposal, to authorise the board of directors, at one or several occasions […]

Bulletin from the 2023 annual general meeting of Xspray Pharma AB (publ)

The following resolutions were passed at the annual general meeting (the “AGM”) of Xspray Pharma AB (publ) (“Xspray”) on 16 May 2023. Adoption of income statement and balance sheet for the financial year 2022 and discharge from liabilityThe AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2022 […]

Interim Report First Quarter 2023

January–March 2023, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -34,827 thousand (-18,934) Earnings per share before dilution amounted to SEK -1.54 (-0.92) Cash flow from operating activities amounted to SEK -45,535 thousand (-27,613) Cash flow from investing activities amounted to SEK -14,650 thousand (-47,541) Significant events during […]

Notice of extraordinary general meeting in Xspray Pharma AB (publ)

The shareholders of Xspray Pharma AB (publ), Reg. No. 556649-3671, (”Xspray Pharma”) are summoned to an extraordinary general meeting on Thursday 25 May 2023 at 13.00 CEST at Advokatfirman Vinge’s office on Smålandsgatan 20 in Stockholm. Registration for the extraordinary general meeting starts at 12.30 CEST. The shareholders may exercise their voting rights at the […]